Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Safety, Tolerability and Initial Efficacy of Pramipexole ER, Given With Aprepitant in Patients With Idiopathic Parkinson's Disease

NCT03683225 is registered in ClinicalTrials.gov with Chase Therapeutics Corporation as lead sponsor.

NCT NCT03683225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03683225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Safety, Tolerability and Initial Efficacy of Pramipexole ER, Given With Aprepitant in Patients With Idiopathic Parkinson's Disease
Lead sponsor
Chase Therapeutics Corporation
Phase
Phase 2
Overall status
Unknown status
Start date
April 1, 2019
Completion date
December 30, 2025
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic parkinson disease